BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 27853930)

  • 21. Management of herpesvirus reactivations in patients with solid tumours and hematologic malignancies: update of the Guidelines of the Infectious Diseases Working Party (AGIHO) of the German Society for Hematology and Medical Oncology (DGHO) on herpes simplex virus type 1, herpes simplex virus type 2, and varicella zoster virus.
    Henze L; Buhl C; Sandherr M; Cornely OA; Heinz WJ; Khodamoradi Y; Kiderlen TR; Koehler P; Seidler A; Sprute R; Schmidt-Hieber M; von Lilienfeld-Toal M
    Ann Hematol; 2022 Mar; 101(3):491-511. PubMed ID: 34994811
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Guide for health professionals addressing oral care for individuals in oncological treatment based on scientific evidence.
    Carvalho CG; Medeiros-Filho JB; Ferreira MC
    Support Care Cancer; 2018 Aug; 26(8):2651-2661. PubMed ID: 29470703
    [TBL] [Abstract][Full Text] [Related]  

  • 23. A systematic review of oral herpetic viral infections in cancer patients: commonly used outcome measures and interventions.
    Elad S; Ranna V; Ariyawardana A; Correa ME; Tilly V; Nair RG; Rouleau T; Logan RM; Pinto A; Charette V; Saunders DP; Jensen SB;
    Support Care Cancer; 2017 Feb; 25(2):687-700. PubMed ID: 27853930
    [TBL] [Abstract][Full Text] [Related]  

  • 24. A systematic review of viral infections associated with oral involvement in cancer patients: a spotlight on Herpesviridea.
    Elad S; Zadik Y; Hewson I; Hovan A; Correa ME; Logan R; Elting LS; Spijkervet FK; Brennan MT;
    Support Care Cancer; 2010 Aug; 18(8):993-1006. PubMed ID: 20544224
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Herpes simplex virus latency, reactivation, and a new antiviral therapy for herpetic keratitis].
    Shimomura Y
    Nippon Ganka Gakkai Zasshi; 2008 Mar; 112(3):247-64; discussion 265. PubMed ID: 18411713
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Systematic reviews of oral complications from cancer therapies, Oral Care Study Group, MASCC/ISOO: methodology and quality of the literature.
    Brennan MT; Elting LS; Spijkervet FK
    Support Care Cancer; 2010 Aug; 18(8):979-84. PubMed ID: 20306090
    [TBL] [Abstract][Full Text] [Related]  

  • 27. MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
    Elad S; Cheng KKF; Lalla RV; Yarom N; Hong C; Logan RM; Bowen J; Gibson R; Saunders DP; Zadik Y; Ariyawardana A; Correa ME; Ranna V; Bossi P;
    Cancer; 2020 Oct; 126(19):4423-4431. PubMed ID: 32786044
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management of oral lesions in HIV-positive patients.
    Baccaglini L; Atkinson JC; Patton LL; Glick M; Ficarra G; Peterson DE
    Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2007 Mar; 103 Suppl():S50.e1-23. PubMed ID: 17379155
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A novel potential therapy for HSV.
    Whitley RJ; Prichard M
    N Engl J Med; 2014 Jan; 370(3):273-4. PubMed ID: 24428473
    [No Abstract]   [Full Text] [Related]  

  • 30. CMX001 to prevent cytomegalovirus disease in hematopoietic-cell transplantation.
    Marty FM; Winston DJ; Rowley SD; Vance E; Papanicolaou GA; Mullane KM; Brundage TM; Robertson AT; Godkin S; Momméja-Marin H; Boeckh M;
    N Engl J Med; 2013 Sep; 369(13):1227-36. PubMed ID: 24066743
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Low-dose acyclovir prophylaxis for the prevention of herpes simplex virus disease after allogeneic hematopoietic stem cell transplantation.
    Kawamura K; Wada H; Yamasaki R; Ishihara Y; Sakamoto K; Ashizawa M; Sato M; Machishima T; Terasako K; Kimura SI; Kikuchi M; Nakasone H; Yamazaki R; Kanda J; Kako S; Tanihara A; Nishida J; Kanda Y
    Transpl Infect Dis; 2013 Oct; 15(5):457-65. PubMed ID: 23895431
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Antiviral agents for herpes simplex virus.
    Vere Hodge RA; Field HJ
    Adv Pharmacol; 2013; 67():1-38. PubMed ID: 23885997
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Heterogeneity and evolution of thymidine kinase and DNA polymerase mutants of herpes simplex virus type 1: implications for antiviral therapy.
    Andrei G; Georgala A; Topalis D; Fiten P; Aoun M; Opdenakker G; Snoeck R
    J Infect Dis; 2013 Apr; 207(8):1295-305. PubMed ID: 23315323
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Acyclovir susceptibility of herpes simplex virus isolates from transplanted and nontransplanted patients in Rio de Janeiro, Brazil.
    Varella RB; Guimarães MA; Guimarães AC; Atalla A; Nucci M; Ramos-e-Silva M
    Skinmed; 2012; 10(4):208-11. PubMed ID: 23008937
    [TBL] [Abstract][Full Text] [Related]  

  • 35.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 36.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 37.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 38.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 39.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.